Iv%2525252525252525252525252525252520dexamethasone

# IV Dexamethasone ## Overview Dexamethasone is a potent, long-acting synthetic glucocorticoid with minimal mineralocorticoid activity. It is characterized by high anti-inflammatory and immunosuppressive potency. ## Primary Indications * Cerebral edema (associated with brain tumors, neurosurgery, or abscess). * Acute severe exacerbations of asthma or COPD. * Bacterial meningitis (adjunctive therapy to prevent neurological sequelae). * Antiemetic prophylaxis for highly emetogenic chemotherapy (CINV). * COVID-19 in hospitalized patients requiring supplemental oxygen. ## Adult Dosing * **Cerebral Edema:** Initial 10 mg IV, followed by 4 mg IV every 6 hours. * **Bacterial Meningitis:** 10 mg IV every 6 hours for 4 days (ideally administered 1–20 minutes before or with the first antibiotic dose). * **CINV Prophylaxis:** 8–20 mg IV as a single dose before chemotherapy. * **COVID-19:** 6 mg IV once daily for up to 10 days. * **Asthma/COPD exacerbations:** 8–10 mg IV once or in divided doses. ## Pediatric Dosing * **Bacterial Meningitis:** 0.15 mg/kg per dose IV every 6 hours for 4 days (start with or before first antibiotic). Max: 10 mg/dose. * **Croup:** 0.6 mg/kg/dose IV or IM as a single dose. Max: 10 mg/dose. * **CINV Prophylaxis:** 0.25–0.5 mg/kg IV once dose. Max: 8–16 mg/dose. * **Status Asthmaticus:** 0.3–0.6 mg/kg IV once dose. Max: 10 mg/dose. ## Dose Adjustments * **Hepatic Impairment:** Clearance may be decreased in severe liver disease; monitor for systemic corticosteroid effects. * **Renal Impairment:** No specific adjustment required. ## Contraindications * Systemic fungal infections. * Known hypersensitivity to dexamethasone or any component. * Administration of live or live-attenuated vaccines during immunosuppressive doses. ## Adverse Effects * **Endocrine:** Hyperglycemia (common, especially in diabetics), adrenal suppression. * **Psychiatric:** Insomnia, mood swings, psychosis, anxiety. * **Gastrointestinal:** Peptic ulcer disease, dyspepsia. * **General:** Fluid retention, hypertension, increased risk of infection, delayed wound healing. ## Key Drug Interactions * **CYP3A4 Inducers (e.g., Phenytoin, Rifampin, Carbamazepine):** Decrease dexamethasone efficacy. * **NSAIDs:** Increased risk of gastrointestinal ulceration/bleeding. * **Antidiabetic agents:** Dexamethasone diminishes the hypoglycemic effect. * **Warfarin:** Variable effects on INR; monitor closely when starting or stopping steroids. ## Monitoring * Serum glucose (frequent checks in diabetic patients). * Blood pressure regularly. * Signs/symptoms of infection. * Serum potassium (for long-term use). * Neuropsychiatric status. ## Clinical Pearls * **Tapering:** Short courses (e.g., < 7 days) generally do not require tapering, but prolonged courses may necessitate a gradual withdrawal to prevent secondary adrenal insufficiency. * **COVID-19 Warning:** Ensure patients are requiring respiratory support; benefit is not established in those not requiring oxygen and may be harmful. * **Administration:** Can be given via IV push (dilution is generally not required, but refer to institutional compatibility charts for Y-site administration). * **Protocol Variance:** Always verify institutional protocols, as dosing for indications like cerebral edema or oncology may significantly vary based on specific department guidelines. *** **Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Dosing and clinical practices should always be verified against the most current institutional prescribing information, drug monographs, and clinical guidelines.